Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


X-Cell Says Estradiol May Offer Greater Restenotic Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Estrogen-based anti-restenotic drug could accelerate healing and have lower rates of stent thrombosis than J&J's Cypher and Boston Scientific's Taxus, according to the firm.

You may also be interested in...

J&J Sues Boston Scientific, Abbott For $5.5 Bil For Breach Of Contract

After losing bidding war for Guidant, J&J charges winning firms with using leaked information.

State Drug Advertising Laws Foreshadow Future Device Regulation

Some state lawmakers contend that industry's voluntary code of ethics is insufficient, according to Kyphon's chief compliance officer.

FDA Official Distinguishes Scientific Exchange From Off-Label Promotion

Agency compliance head Tim Ulatowski says he's not concerned about the scientific exchange of information on products.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts